Current status of immunotherapy for sarcomas

Immunotherapy. 2017 Dec;9(16):1331-1338. doi: 10.2217/imt-2017-0101.


Although the development of anticancer drugs has improved the outcomes of bone and soft tissue sarcomas, the clinical outcome of patients with relapsed sarcomas remains unsatisfactory due to therapeutic toxicities and resistance to anticancer drugs. Therefore, novel therapeutic modalities are needed to improve the outcome of patients with bone and soft tissue sarcomas. Dendritic cells present tumor antigens and stimulate immune responses, and immune cells, such as cytotoxic T lymphocytes, kill tumor cells by recognizing tumor antigens. However, immune-suppressive conditions by immune regulator PD-1, CTLA-4 and regulatory T cells help tumor growth and progression. In this report, current immunotherapies including cellular immunotherapy and checkpoint inhibitors are introduced, and the advantages and disadvantages of the treatments are discussed.

Keywords: clinical trial; immunotherapy; sarcoma.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Bone Neoplasms / immunology
  • Bone Neoplasms / therapy*
  • Costimulatory and Inhibitory T-Cell Receptors / immunology
  • Humans
  • Immunotherapy / methods*
  • Sarcoma / immunology
  • Sarcoma / therapy*
  • Soft Tissue Neoplasms / immunology
  • Soft Tissue Neoplasms / therapy*
  • T-Lymphocytes, Cytotoxic / immunology*
  • T-Lymphocytes, Cytotoxic / transplantation
  • Tumor Escape
  • Tumor Microenvironment


  • Antibodies, Monoclonal
  • Costimulatory and Inhibitory T-Cell Receptors